Prostate Cancer Spread: RNA Networks in Angiogenesis and Metastasis
Estimated reading time: 5 minutes
Prostate cancer remains a major health challenge worldwide, particularly because its spread to other organs causes most patient deaths. To better understand this process, scientists are investigating the molecular mechanisms that drive metastasis. In this context, recent research published in Biology of Reproduction examines a complex network involving long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and messenger RNAs (mRNAs). Together, these molecules regulate cancer-related processes and may influence how prostate cancer develops and spreads.
Importantly, the study offers insights into these molecular interactions and points to potential therapeutic targets. As a result, understanding these networks could help researchers develop more effective treatments. In this article, we explain the findings in simple terms, introduce the key molecular players, and discuss their possible clinical significance and future directions for prostate cancer care.
Key Takeaways
- LncRNA–miRNA–mRNA networks regulate angiogenesis in prostate tumors
- These networks control metastatic progression through multiple pathways
- Targeting these molecular interactions offers new therapeutic opportunities
- Biomarkers derived from these networks may improve early detection
- Current research focuses on translating these findings into clinical applications
The Molecular Basis of Prostate Cancer Spread

Prostate cancer spread is a complex, multi-step process. First, cancer cells break away from the primary tumour. Next, they enter nearby blood vessels or lymphatic vessels. Finally, they travel to distant organs, where they may establish new tumours. Throughout this cascade, coordinated changes in gene expression help cancer cells survive and spread.
To better understand these changes, Zhang et al. (2024) examined how non-coding RNAs regulate prostate cancer progression. In particular, the researchers focused on angiogenesis—the formation of new blood vessels. Because growing tumours need oxygen and nutrients, these vessels can support tumour growth. Moreover, they may provide cancer cells with routes into the circulation.
The study also identifies lncRNAs that may promote angiogenesis by acting as “sponges” for miRNAs. In other words, these lncRNAs bind to miRNAs and reduce their ability to regulate target genes. As a result, certain mRNAs can produce proteins involved in blood-vessel formation. For example, VEGF expression may increase under the influence of lncRNAs. In turn, VEGF stimulates endothelial-cell growth and can increase blood-vessel permeability. Consequently, tumours may receive more nutrients, while cancer cells may find it easier to enter the bloodstream.
Key lncRNAs in Metastatic Progression
Several lncRNAs show altered expression in metastatic prostate cancer. For example, MALAT1 is often upregulated in aggressive tumours. Moreover, this lncRNA may promote cell migration and invasion while also enhancing angiogenesis by sequestering miRNAs. Similarly, HOTAIR is associated with a poorer prognosis. In addition, it activates genes involved in epithelial–mesenchymal transition (EMT). As a result, cancer cells may become more mobile and better able to spread.
Another important lncRNA is PCAT1. It interacts with multiple miRNAs and, therefore, contributes to a complex regulatory network. When PCAT1 is overexpressed, metastatic potential may increase. Overall, the researchers identified dozens of dysregulated lncRNAs, each of which may contribute to different aspects of cancer progression. However, the key challenge is determining which lncRNAs are primary drivers of metastasis and which are associated changes.
How These Networks Function in Angiogenesis
Angiogenesis depends on precise molecular coordination. According to the study, lncRNA–miRNA–mRNA networks help regulate this process. Initially, low oxygen levels within tumours trigger a response by activating HIF-1α, a transcription factor. In turn, HIF-1α can induce the expression of certain lncRNAs. These lncRNAs may then sequester miRNAs that would otherwise target angiogenesis-related factors. Consequently, production of VEGF, FGF, and other growth factors may increase.
Following this growth-factor stimulation, endothelial cells proliferate and form new blood vessels. At the same time, they produce matrix metalloproteinases (MMPs), enzymes that break down surrounding tissue. As a result, vessels can extend into tumor masses.
Beyond vessel formation, these molecular networks also influence vascular permeability. When permeability is more tightly regulated, metastatic potential may be reduced. Finally, the study identifies several mRNAs that may contribute to blood-vessel stabilisation.
Role of These Networks in Metastatic Cascades
Cancer spreads in several steps, not just by growing new blood vessels. The study looks at how lncRNAs, miRNAs, and mRNAs may affect each step. First, cancer cells begin to move. Changes in cell proteins help them move more easily. They can then enter nearby tissue. Matrix metalloproteinases help break down the tissue around them. Next, some cancer cells enter blood vessels. Changes in cell-adhesion molecules may help them break away from the main tumor. After that, they travel through the blood.
The study also points to mRNAs that may help cancer cells avoid anoikis, a type of cell death that can happen when cells detach from their usual surroundings. This may help some cancer cells survive while they travel.
Frequently Asked Questions
LncRNAs act as molecular sponges for miRNAs. They bind these suppressive molecules and neutralise their activity. This allows expression of genes that promote angiogenesis and metastasis. Their dysregulation contributes significantly to aggressive disease.
The study identified hundreds of dysregulated interactions. Key networks involve lncRNAs like MALAT1 and HOTAIR. These molecules sequester miRNAs such as miR-34a and miR-200 family members. This allows expression of target mRNAs including VEGF and matrix metalloproteinases.
Several therapeutic approaches exist. Antisense oligonucleotides can degrade oncogenic lncRNAs. miRNA mimics can restore tumor suppressor function. Small molecules can affect network components. Many agents remain in preclinical development. Clinical trials continue for some candidates.
Reference:
- Puente-Rivera, J., Nuñez Olvera, S. I., Robles-Chávez, A. E., Nieto-Velázquez, N. G., & Alvarez-Sánchez, M. E. (2026). Transcriptomic Insights into lncRNA–miRNA–mRNA Networks Regulating Angiogenesis and Metastasis in Prostate Cancer. BioTech, 15(1), 12. https://doi.org/10.3390/biotech15010012


